In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ACNAP Silver Members, Fellows of the ESC and Young combined Members

Barriers to medication adherence in patients with cardiovascular disease from 12 countries: survey results from the EUROASPIRE V collaborative study

Session Moderated poster session - Public health and cardiac rehabilitation

Speaker Catriona Sian Jennings

Congress : EuroHeartCare 2019

  • Topic : preventive cardiology
  • Sub-topic : Stress, Psycho-Social and Cultural Aspects of Heart Disease
  • Session type : Moderated Posters
  • FP Number : 23

Authors : C S Jennings (London,GB), F Astin (Huddersfield,GB), E Prescott (Copenhagen,DK), T Hansen (Copenhagen,DK), C Gale (Leeds,GB), D De Bacquer (Gent,BE)

C S Jennings1 , F Astin2 , E Prescott3 , T Hansen4 , C Gale5 , D De Bacquer6 , 1Imperial College London - London - United Kingdom of Great Britain & Northern Ireland , 2University of Huddersfield - Huddersfield - United Kingdom of Great Britain & Northern Ireland , 3University of Copenhagen - Copenhagen - Denmark , 4Zealand University Hospital - Copenhagen - Denmark , 5University of Leeds - Leeds - United Kingdom of Great Britain & Northern Ireland , 6Ghent University - Gent - Belgium ,



Background: Adherence to cardiovascular medications is an imperative for reducing mortality after a cardiac event.

Purpose: To measure barriers to adherence to cardiovascular medications in participants with cardiovascular disease.

Methods: As part of the EUROASPIRE V study conducted in patients admitted to hospital 6-24 months earlier with ACS, a sub-sample of 3408 participants (76% male, mean age 64 years) from 12 countries (Egypt, Ireland, Kazakhstan, Lithuania, Netherlands, Poland, Portugal, Russian Federation, Sweden, Turkey, Ukraine, United Kingdom) were asked about their adherence to drugs to modify blood pressure, lipids and glucose: "Since the index event how often did you take your medications as the doctor prescribed?" The options for reply included: all of the time (100%), nearly all of the time (75%), most of the time (75%), about half the time (50%) and less than half the time (<50%).

Results: Overall non-adherence was self-rated at 9% (7% lipid lowering drugs; 5% antihypertensives; 7% hypoglycaemics) varying between 0% in Netherlands and 31% in Ukraine. Higher education was associated with less non-adherence (9% high v. 14% low); as was higher income (7% high v. 14% low). Non-adherence was highest in patients taking one class of drug (14%) compared to those on two (8%) or three (9%): p=0.04. 65% of patients were prescribed more than 2 drug classes. Non- adherence was higher in those not attending cardiac rehabilitation (13% attenders v. 5% non-attenders: p<0.001). Non-adherence was associated with anxiety (HADS r=+0.06) and depression (HADS r=+0.12) and lower ratings of health-related quality of life according to EQ-VAS (r =-0.11) and HeartQol global (r=-0.08).

Conclusion: Non-adherence to cardiovascular medications is associated with adverse psychosocial profiles. Educational initiatives like cardiac rehabilitation provide important interventions to promote adherence.

The free consultation period for this content is over.

It is now only available year-round to ACNAP Silver Members, Fellows of the ESC and Young combined Members

Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from ESC Congress and ESC Asia with APSC & AFC
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s congress resources
  • 3Under 40 or in training - with a Combined Membership, access resources from all congresses
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are